Lumos Pharma Inc
NASDAQ:LUMO

Watchlist Manager
Lumos Pharma Inc Logo
Lumos Pharma Inc
NASDAQ:LUMO
Watchlist
Price: 4.34 USD Market Closed
Market Cap: 37.5m USD

Lumos Pharma Inc
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Lumos Pharma Inc
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Lumos Pharma Inc
NASDAQ:LUMO
Operating Income
-$36.3m
CAGR 3-Years
-4%
CAGR 5-Years
-15%
CAGR 10-Years
1%
Abbvie Inc
NYSE:ABBV
Operating Income
$19.7B
CAGR 3-Years
0%
CAGR 5-Years
9%
CAGR 10-Years
13%
Gilead Sciences Inc
NASDAQ:GILD
Operating Income
$11.3B
CAGR 3-Years
6%
CAGR 5-Years
7%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Operating Income
$12.1B
CAGR 3-Years
6%
CAGR 5-Years
6%
CAGR 10-Years
4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Operating Income
$4.5B
CAGR 3-Years
2%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Operating Income
$3.9B
CAGR 3-Years
-17%
CAGR 5-Years
4%
CAGR 10-Years
12%
No Stocks Found

Lumos Pharma Inc
Glance View

Market Cap
37.5m USD
Industry
Biotechnology

Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for rare diseases. The company is headquartered in Austin, Texas and currently employs 29 full-time employees. The company went IPO on 2011-11-11. The firm is focused on identifying, acquiring, developing, and commercializing products and therapies for people with rare diseases. Its lead product candidate is LUM-201, a therapy for pediatric growth hormone deficiency (PGHD) and other rare endocrine disorders. LUM-201 stimulates growth hormone (GH) through the GH secretagogue receptor. Its product provides a differentiated mechanism of action to treat rare endocrine disorders by increasing the amplitude of endogenous and pulsatile GH secretion. LUM-201 is an orally administered small molecule, which is a GH secretagogue for rare endocrine disorders where injectable recombinant human growth hormone (rhGH) is approved. Its pipeline features development programs for rare diseases associated with growth hormone deficiencies. Its subsidiaries include NewLink International, BlueLink Pharmaceuticals, Inc, BioProtection Systems Corporation and Lumos Pharma Sub, Inc.

LUMO Intrinsic Value
11.02 USD
Undervaluation 61%
Intrinsic Value
Price

See Also

What is Lumos Pharma Inc's Operating Income?
Operating Income
-36.3m USD

Based on the financial report for Sep 30, 2024, Lumos Pharma Inc's Operating Income amounts to -36.3m USD.

What is Lumos Pharma Inc's Operating Income growth rate?
Operating Income CAGR 10Y
1%

Over the last year, the Operating Income growth was -3%. The average annual Operating Income growth rates for Lumos Pharma Inc have been -4% over the past three years , -15% over the past five years , and 1% over the past ten years .

Back to Top